PharmaEssentia Corporation

TWSE:6446 Voorraadrapport

Marktkapitalisatie: NT$205.7b

PharmaEssentia Beheer

Beheer criteriumcontroles 3/4

De CEO PharmaEssentia is Ko-Chung Lin, benoemd in Jan2017, heeft een ambtstermijn van 7.83 jaar. bezit rechtstreeks 1.73% van de aandelen van het bedrijf, ter waarde NT$ 3.56B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.1 jaar en 3.3 jaar.

Belangrijke informatie

Ko-Chung Lin

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEO7.8yrs
Eigendom CEO1.7%
Management gemiddelde ambtstermijn5.1yrs
Gemiddelde ambtstermijn bestuur3.3yrs

Recente managementupdates

Recent updates

We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

Aug 20
We Think That There Are Issues Underlying PharmaEssentia's (TWSE:6446) Earnings

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Jul 02
PharmaEssentia Corporation's (TWSE:6446) 37% Price Boost Is Out Of Tune With Revenues

Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Apr 02
Is There An Opportunity With PharmaEssentia Corporation's (TWSE:6446) 25% Undervaluation?

Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

Mar 18
Downgrade: Here's How Analysts See PharmaEssentia Corporation (GTSM:6446) Performing In The Near Term

PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 06
PharmaEssentia Corporation (GTSM:6446) Just Reported And Analysts Have Been Cutting Their Estimates

Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

Mar 04
Things Look Grim For PharmaEssentia Corporation (GTSM:6446) After Today's Downgrade

PharmaEssentia (GTSM:6446) Is Using Debt Safely

Feb 10
PharmaEssentia (GTSM:6446) Is Using Debt Safely

What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Jan 06
What Type Of Returns Would PharmaEssentia's(GTSM:6446) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?

Analyse CEO-vergoeding

Hoe is Ko-Chung Lin's beloning veranderd ten opzichte van PharmaEssentia's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

NT$1b

Mar 31 2024n/an/a

NT$442m

Dec 31 2023n/an/a

-NT$624m

Sep 30 2023n/an/a

-NT$890m

Jun 30 2023n/an/a

-NT$1b

Mar 31 2023n/an/a

-NT$2b

Dec 31 2022n/an/a

-NT$1b

Sep 30 2022n/an/a

-NT$2b

Jun 30 2022n/an/a

-NT$2b

Mar 31 2022n/an/a

-NT$3b

Dec 31 2021NT$9mNT$9m

-NT$3b

Sep 30 2021n/an/a

-NT$3b

Jun 30 2021n/an/a

-NT$3b

Mar 31 2021n/an/a

-NT$2b

Dec 31 2020NT$9mNT$9m

-NT$2b

Sep 30 2020n/an/a

-NT$1b

Jun 30 2020n/an/a

-NT$862m

Mar 31 2020n/an/a

-NT$856m

Dec 31 2019NT$9mNT$8m

-NT$843m

Compensatie versus markt: Er zijn onvoldoende gegevens om vast te stellen of de totale vergoeding van Ko-Chung redelijk is in vergelijking met bedrijven van vergelijkbare omvang in de TW markt.

Compensatie versus inkomsten: De vergoeding van Ko-Chung is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ko-Chung Lin

7.8yrs

Tenure

NT$9,389,000

Compensatie

Mr. Ko-Chung Lin, Ph D., is the Founder and Chief Strategy Officer of PharmaEssentia Corporation and has been its Chief Executive Officer since January 01, 2017. He also serves as a Director at PharmaEssen...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12.2yrsNT$8.49m1.05%
NT$ 2.2b
Ko-Chung Lin
Founder7.8yrsNT$9.39m1.73%
NT$ 3.6b
Chan-Kou Hwang
Presidentno dataNT$8.49m0.61%
NT$ 1.2b
Snow Chang
Accounting Manager & Senior Manager of Finance9.1yrsgeen gegevensgeen gegevens
Samuel Lin
VP and Head of Business Operations & Strategy2.8yrsgeen gegevensgeen gegevens
Lih-Ling Lin
Chief Scientific Officer2.3yrsgeen gegevens0.010%
NT$ 21.0m
Rachel Lipsitz
VP and Head of Corporate Communications & Advocacy2.8yrsgeen gegevensgeen gegevens
Roddy Mcilwain
Senior VP and Head of Sales & Marketing3.8yrsgeen gegevensgeen gegevens
Anjana Pursnani
Senior VP & Head of People2.8yrsgeen gegevensgeen gegevens
Albert Qin
Chief Medical Officer7.8yrsgeen gegevens0.0061%
NT$ 12.5m
Narihisa Miyachi
Head of Japan Medical Affairs6.3yrsgeen gegevensgeen gegevens
Yen-Tung Luan
Chief Operating Officer of Taichung Plant6.3yrsgeen gegevensgeen gegevens

5.1yrs

Gemiddelde duur

Ervaren management: Het managementteam van 6446 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.1 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ching-Leou Teng
Chairman & Chief Pharmaceutical Officer12.2yrsNT$8.49m1.05%
NT$ 2.2b
Ko-Chung Lin
Founder3.3yrsNT$9.39m1.73%
NT$ 3.6b
Chan-Kou Hwang
President9.5yrsNT$8.49m0.61%
NT$ 1.2b
Jeffrey R. Williams
Independent Directorless than a yeargeen gegevensgeen gegevens
Ching-Tsun Liu
Independent Directorless than a yeargeen gegevens0.13%
NT$ 260.5m
Jinn-Der Chang
Independent Director10.7yrsNT$120.00k0.029%
NT$ 59.1m
Jien-Heh Tien
Independent Director6.4yrsNT$120.00k0.00060%
NT$ 1.2m
Ming-Chuan Hsieh
Independent Directorless than a yeargeen gegevens0.0012%
NT$ 2.5m
Norio Komatsu
Chairperson of Japan3.5yrsgeen gegevensgeen gegevens
Shen Yi Li
Director3.3yrsNT$95.00k0.24%
NT$ 502.1m
HsuehFang Hsu
Directorless than a yeargeen gegevensgeen gegevens
ChenJung Hsiao
Directorless than a yeargeen gegevensgeen gegevens

3.3yrs

Gemiddelde duur

Ervaren bestuur: De raad van bestuur van 6446 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.3 jaar).